Low-Dose Tenecteplase in Covid-19

Summary

Low-Dose Tenecteplase in Covid-19 is a clinical trial^[1].

Key Facts

• Low-Dose Tenecteplase in Covid-19 is in the country of United States^[2].
• Low-Dose Tenecteplase in Covid-19's instance of is recorded as clinical trial^[3].
• Low-Dose Tenecteplase in Covid-19's start time is recorded as +2020-09-08T00:00:00Z^[4].
• Low-Dose Tenecteplase in Covid-19's end time is recorded as +2021-12-31T00:00:00Z^[5].
• Low-Dose Tenecteplase in Covid-19's main subject is recorded as pulmonary embolism^[6].
• Low-Dose Tenecteplase in Covid-19's main subject is recorded as embolism^[7].
• Low-Dose Tenecteplase in Covid-19's number of participants is recorded as {'unit': '1', 'amount': '+45'}^[8].
• Low-Dose Tenecteplase in Covid-19's title is recorded as Low-Dose Tenecteplase in Covid-19 Patients With Acture Pulmonary Embolism: A Randomized, Double-Blind, Placebo-Controlled Trial^[9].
• Low-Dose Tenecteplase in Covid-19's minimum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+18'}^[10].
• Low-Dose Tenecteplase in Covid-19's ClinicalTrials.gov ID is recorded as NCT04558125^[11].
• Low-Dose Tenecteplase in Covid-19's maximum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+75'}^[12].
• Low-Dose Tenecteplase in Covid-19's research intervention is recorded as tenecteplase^[13].
• Low-Dose Tenecteplase in Covid-19's clinical trial phase is recorded as phase IV clinical trial^[14].
• Low-Dose Tenecteplase in Covid-19's research site is recorded as Cedars-Sinai Medical Center^[15].
• Low-Dose Tenecteplase in Covid-19's research subject recruitment status is recorded as active, not recruiting^[16].
• Low-Dose Tenecteplase in Covid-19's study type is recorded as interventional study^[17].